{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-24-000079","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2024-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.690171+00:00","generated_at":"2026-06-05T05:31:40.841976+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioVie's NE3107 shows PD Phase 2a non-motor symptom improvement; AD Phase 3 misses significance but biomarker gains","bullets":["PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.","PD: 26% of NE3107 patients had better morning motor scores vs 0% placebo (p=0.046); younger patients saw >6 point UPDRS advantage.","AD Phase 3 missed significance per protocol; NE3107 showed 68% slowing of decline on CDR-SB and 26% on ADAS-COG-12.","AD biomarkers: NE3107 associated with biological age deceleration -3.87 years (p=0.012), reduced fasting glucose and cholesterol.","Principal component analysis suggests NE3107 may realign metabolic inflammation; data presented at AD/PD 2024 in Lisbon."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-24-000079","json":"https://secwatch.observer/filing/0001520138-24-000079.json","markdown":"https://secwatch.observer/filing/0001520138-24-000079.md","text":"https://secwatch.observer/filing/0001520138-24-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/0001520138-24-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/bivi-20240301_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T05:31:40.841976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}